KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Invested Capital (2016 - 2026)

Moderna (MRNA) has disclosed Invested Capital for 11 consecutive years, with $7.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital fell 26.43% year-over-year to $7.5 billion; the TTM value through Mar 2026 reached $7.5 billion, down 26.43%, while the annual FY2025 figure was $9.2 billion, 15.72% down from the prior year.
  • Invested Capital hit $7.5 billion in Q1 2026 for Moderna, down from $9.2 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $20.2 billion in Q4 2022 and bottomed at $7.5 billion in Q1 2026.
  • Average Invested Capital over 5 years is $14.0 billion, with a median of $13.4 billion recorded in 2024.
  • Year-over-year, Invested Capital surged 344.69% in 2022 and then plummeted 32.52% in 2024.
  • Moderna's Invested Capital stood at $20.2 billion in 2022, then dropped by 28.56% to $14.4 billion in 2023, then decreased by 24.02% to $11.0 billion in 2024, then fell by 15.72% to $9.2 billion in 2025, then fell by 19.35% to $7.5 billion in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $7.5 billion, $9.2 billion, and $9.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.